Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance
Open Access
- 8 December 2008
- journal article
- review article
- Published by Frontiers Media SA in Transplant International
- Vol. 22 (1) , 96-109
Abstract
Introduction of new innovative immunosuppressive strategies has been the milestone of the recent evolution of intestinal and multivisceral transplantation. With new insights into the mechanisms of organ engraftment and acquired tolerance, the Pittsburgh tolerogenic protocol was recently introduced and consisted of two main therapeutic principles: recipient pretreatment with lymphoid ablating antibodies and minimal post‐transplant immunosuppression with tacrolimus monotherapy. The reported herein improved survival and the striking ability to wean immunosuppression among the intestinal and multivisceral recipients pretreated with a single‐dose of Thymoglobulin (rATG) or Campath‐1H (alemtuzumab) supports our working hypothesis with successful induction of variable tolerance. It is important, however, that careful monitoring of subtle histologic changes in serial endoscopic‐guided mucosal biopsies be carried out for early diagnosis of allograft immune activation with prompt restoration of the baseline immunosuppressive therapy. Future scientific discoveries with better understanding of the mechanisms of immune tolerance and clinical introduction of reliable assays will increase the chance and safety of achieving complete tolerance among the intestinal and other solid organ recipients. This review will focus on the historic evolution of the immunosuppressive and other management strategies utilized for the intestinal and multivisceral recipients at the University of Pittsburgh with special reference to allograft immunity and the successful achievement of partial tolerance.Keywords
This publication has 47 references indexed in Scilit:
- NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestineGut, 2007
- Tolerogenic Protocol for Intestinal TransplantationTransplantation Proceedings, 2006
- Tolerogenic protocols for intestinal transplantationTransplant Immunology, 2004
- RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)Transplantation, 2003
- Preliminary experience with campath 1H (C1H) in intestinal and liver transplantationTransplantation, 2003
- Transplantation tolerance from a historical perspectiveNature Reviews Immunology, 2001
- INTESTINAL TRANSPLANTATION: 1997 REPORT OF THE INTERNATIONAL REGISTRY1-3Transplantation, 1999
- Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipientsThe Lancet, 1998
- Clinical Intestinal Transplantation: New Perspectives and Immunologic Considerations 1 1This study was supported in part by Project Grant No. DK 29661 from the National Institutes of Health, Bethesda, MD.Journal of the American College of Surgeons, 1998
- Outcome Analysis of 71 Clinical Intestinal TransplantationsAnnals of Surgery, 1995